Moderna, Inc. Operating Expenses
Moderna, Inc. (MRNA) reported Operating Expenses of $393.03 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-10-30
- Moderna, Inc. operating expenses for the quarter ending 2020-09-30 was $393.03M, a 165.90% increase year-over-year.
- Moderna, Inc. operating expenses for the quarter ending 2020-06-30 was $188.48M, a 20.21% increase year-over-year.
- Moderna, Inc. operating expenses for the quarter ending 2020-03-31 was $139.25M, a 11.68% decline year-over-year.
- Moderna, Inc. operating expenses for the quarter ending 2019-12-31 was $144.61M, a 23.26% decline year-over-year.
- Moderna, Inc. operating expenses for fiscal 2019 was $605.93M, a 10.50% increase from fiscal 2018.
- Moderna, Inc. operating expenses for fiscal 2018 was $548.33M, a 15.39% increase from fiscal 2017.
- Moderna, Inc. operating expenses for fiscal 2017 was $475.18M, a 43.05% increase from fiscal 2016.
- Moderna, Inc. operating expenses for fiscal 2016 was $332.17M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2020-09-30 | $393.03M 10-Q · filed 2020-10-30 | $581.50M derived: sum of 2 quarters · filed 2020-10-30 | $720.76M 10-Q · filed 2020-10-30 | $865.37M derived: sum of 4 quarters · filed 2020-10-30 | |||
| 2020-06-30 | $188.48M 10-Q · filed 2020-08-06 | $327.73M 10-Q · filed 2020-08-06 | $472.34M derived: sum of 3 quarters · filed 2020-08-06 | $620.15M derived: sum of 4 quarters · filed 2020-10-30 | |||
| 2020-03-31 | $139.25M 10-Q · filed 2020-05-07 | $283.86M derived: sum of 2 quarters · filed 2020-05-07 | $431.67M derived: sum of 3 quarters · filed 2020-10-30 | $588.46M derived: sum of 4 quarters · filed 2020-10-30 | |||
| 2019-12-31 | $144.61M 10-K · filed 2020-02-27 | $292.42M derived: sum of 2 quarters · filed 2020-10-30 | $449.21M derived: sum of 3 quarters · filed 2020-10-30 | $605.93M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $147.81M 10-Q · filed 2020-10-30 | $147.90M 10-Q · filed 2019-11-06 | $304.60M derived: sum of 2 quarters · filed 2020-10-30 | $462.27M 10-Q · filed 2020-10-30 | $462.78M 10-Q · filed 2019-11-06 | $650.72M derived: sum of 4 quarters · filed 2020-10-30 | |
| 2019-06-30 | $156.79M 10-Q · filed 2020-08-06 | $157.02M 10-Q · filed 2019-08-08 | $314.46M 10-Q · filed 2020-08-06 | $314.88M 10-Q · filed 2019-08-08 | $502.91M derived: sum of 3 quarters · filed 2020-08-06 | $630.49M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $157.67M 10-Q · filed 2020-05-07 | $157.86M 10-Q · filed 2019-05-09 | $346.12M derived: sum of 2 quarters · filed 2020-05-07 | $473.69M derived: sum of 3 quarters · filed 2020-05-07 | $599.56M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $188.45M 10-K · filed 2020-02-27 | $316.03M derived: sum of 2 quarters · filed 2020-02-27 | $441.89M derived: sum of 3 quarters · filed 2020-02-27 | $548.33M 10-K · filed 2020-02-27 | |||
| 2018-09-30 | $127.58M 10-K · filed 2020-02-27 | $253.44M derived: sum of 2 quarters · filed 2020-02-27 | $359.88M 10-Q · filed 2019-11-06 | $493.61M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $125.87M 10-K · filed 2020-02-27 | $232.31M 10-Q · filed 2019-08-08 | $366.04M derived: sum of 3 quarters · filed 2020-02-27 | $476.38M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $106.44M 10-K · filed 2020-02-27 | $240.17M derived: sum of 2 quarters · filed 2020-02-27 | $350.52M derived: sum of 3 quarters · filed 2020-02-27 | $485.83M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $133.73M 10-K · filed 2019-03-13 | $244.07M derived: sum of 2 quarters · filed 2019-03-13 | $379.39M derived: sum of 3 quarters · filed 2019-03-13 | $475.18M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $110.34M 10-K · filed 2019-03-13 | $245.66M derived: sum of 2 quarters · filed 2019-03-13 | $341.45M derived: sum of 3 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $135.31M 10-K · filed 2019-03-13 | $231.11M derived: sum of 2 quarters · filed 2019-03-13 | |||||
| 2017-03-31 | $95.79M 10-K · filed 2019-03-13 | ||||||
| 2016-12-31 | $332.17M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |